Back to Trial

Oracle Runs

Oracle findings and outcome history for A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD (NCT05643638).

Runs
5
Findings
5
Latest Run
Apr 6, 2026, 2:57 PM
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)

Will the results be positive?

Trial NCT05643638 remains ongoing (recruiting status per ClinicalTrials.gov). Primary eval period completed Mar 2026; topline results expected June 2026. No public readout available as of Apr 2026. Prior Phase 1 positive, but no Phase 2 data.

Found Apr 6, 2026, 2:58 PMReviewed Apr 6, 2026, 3:00 PM
ClinicalTrialsclinicaltrials.gov
A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD
Current status: Recruiting. Estimated primary completion: 2026-03-01.
Web Searchtheglobeandmail.comMar 30, 2026, 12:00 AM
Cynata Reaches Key Phase 2 Milestone in aGvHD as Late-stage Cell Therapy Pipeline Advances
Primary evaluation period complete for all 65 participants. Data compiled/analyzed ahead of results readout expected June 2026.
Web Searchbiospace.comDec 15, 2025, 12:00 AM
Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial
Primary evaluation period expected to complete March 2026, results anticipated June 2026.
NO_DECISIONDismissed95% confidenceGrok 4.20 (xAI)

Will the results be positive?

No public readout available. Phase 2 trial (NCT05643638) completed 100-day primary evaluation in Mar 2026; topline ORR results expected June 2026. Current status is recruiting per record but announcements confirm data analysis ongoing. Prior Phase 1 data positive but not this exact trial. Evidence incomplete and pre-readout.

Found Apr 6, 2026, 2:09 PMReviewed Apr 6, 2026, 2:25 PM
Web Searchafr.comMar 30, 2026, 4:00 AM
100-Day Primary Evaluation Period Complete in Phase 2 aGvHD Clinical Trial
100-day primary evaluation complete for all participants. Data compiled and analysed. Primary endpoint ORR at Day 28, results anticipated in June 2026.
Web Searchtheglobeandmail.comMar 30, 2026, 4:00 AM
Cynata Reaches Key Phase 2 Milestone in aGvHD as Late-Stage Cell Therapy Pipeline Advances
Completed 100-day primary evaluation for all 65 participants. Data being compiled and analyzed ahead of results readout expected in June 2026.
ClinicalTrialsclinicaltrials.gov
A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD
Current status: Recruiting. Estimated primary completion: 2026-03-01. No results posted. Primary endpoint: ORR at 28 days.
NO_DECISIONDismissed97% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No trial-specific efficacy readout is public yet. ClinicalTrials.gov still showed the study record updated on 2025-12-05, and recent coverage says the 100-day evaluation just finished with data being compiled and a results readout expected in June 2026. Without actual results, positive vs negative cannot be classified.

Found Apr 3, 2026, 4:30 PMReviewed Apr 3, 2026, 4:47 PM
ClinicalTrialsclinicaltrials.govDec 5, 2025, 12:00 AM
Study Details | NCT05643638 | A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD
ClinicalTrials.gov study record for NCT05643638 was last updated/posted in Dec. 2025, indicating the trial record was still active and not accompanied by posted results.
Web Searchbiospace.comDec 14, 2025, 12:00 AM
Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial
Company press release reported enrollment completion and said the study’s primary evaluation period was expected to conclude in March 2026, with results anticipated in June 2026.
Web Searchtipranks.com
Cynata Reaches Key Phase 2 Milestone in aGvHD as Late-Stage Cell Therapy Pipeline Advances
States Cynata completed the 100-day primary evaluation period for all participants and that data are being compiled/analyzed ahead of a results readout expected in June 2026.
NO_DECISIONDismissed94% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No trial-specific efficacy readout is publicly available yet. Sponsor materials and the enrollment-completion announcement both state the Phase 2 aGvHD results are expected in June/Q2 2026, so there is not enough evidence to call this exact trial positive or negative as of 2026-04-01.

Found Apr 1, 2026, 7:15 PMReviewed Apr 1, 2026, 7:16 PM
Sponsorbiospace.comDec 15, 2025, 12:00 AM
Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial
Cynata said enrolment is complete; the 100-day primary evaluation period should finish in March 2026, with results anticipated around June 2026.
Sponsorcompany-announcements.afr.comMar 1, 2026, 12:00 AM
ASX announcement / investor presentation
Sponsor slide deck says for the Phase 2 aGvHD trial: enrolment completed Dec 2025 and readout timing/results expected June 2026 / Q2 CY26.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

No oracle outcome history is available for this trial yet.